Working in a publicly-funded health service, I would like to know of any cost-benefit analysis of Nirsevimab vs our current use of Palivizumab. If this is not available yet, are you able to tell us when/ how this data will become available to us? And if you are proposing a broadening of the categories of infants who receive RSV prophylaxis, would you do a separate cost-benefit analysis for eg. healthy term infants?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.